ArcticZymes Technologies ASA: Notice of Annual General Meeting 26
The annual general meeting ("AGM") for ArcticZymes Technologies ASA will be held on Thursday 28. May 2026 at 12.00 CET. The meeting will be held as a physical meeting, with an option for shareholders to participate digitally.
ArcticZymes Technologies Delivers 36% Sales Growth in Q1 2026, with Molecular Tools Rebound and Biomanufacturing Momentum
Tromsø, Norway, May 7, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported first-quarter 2026 results, with sales up 36% year-on-year to NOK 31.8 million and positive EBITDA — a NOK 5.3 million turnaround versus Q1 2025. Growth was broad-based across both business segments, with Molecular Tools rebounding sharply and Biomanufacturing extending its commercial reach among global CDMOs.
ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing
ArcticZymes today announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company’s strategic expansion into the rapidly growing RNA therapeutics manufacturing market.
ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing
ArcticZymes Technologies today announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program.
ArcticZymes Technologies ASA Capital Markets Day 2026 [Video]
Watch ArcticZymes’ management team outline the strategy to scale and diversify its enzyme platform across biomanufacturing and molecular tools.